News on molecular diagnostics, pharmacogenomics tests for coronary artery disease, congenital heart defects, and more.
They have developed a prototype assay that requires only a drop of blood and relies on an immunoreaction that blocks electrons to enable CRP measurement.
Practice recommendations could serve as a guide for labs considering using the high-sensitivity assays as they become available, authors said.
The company has been focused on commercializing its technology for heart attack assessment, but the new data shows how it could be used for CAD risk, as well.
The company will pay the US $33.2 million to settle allegations that it caused hospitals to submit false claims to federal healthcare programs.
The prospective analysis suggests that the approach could help clinicians identify patients at risk of a stroke who could benefit from anticoagulant treatment.
